治疗性心脏停搏作为复苏性主动脉血管内球囊阻断的辅助手段:在猪模型中架起致命性出血到确定性外科控制的桥梁
该研究为猪模型随机对照实验,比较单纯REBOA与ALM-REBOA(n=8/组)在非压迫性躯干出血中的效果。损伤后1分钟给ALM,7分钟后行Zone 1 REBOA充气,T30外科止血并放气,复苏至T90。ALM-REBOA组总失血量显著减少(17.75±2.04 vs 24.32±1.89 mL/kg,p=0.0499),生存率无显著差异(89% vs 100%)。结论提示ALM可作为REBOA放置前的桥接治疗减少失血。
要点
- 在猪非压迫性躯干出血模型中,ALM-REBOA组总失血量显著低于单纯REBOA组(17.75±2.04 vs 24.32±1.89 mL/kg,p=0.0499)。
- ALM-REBOA组生存率89%,单纯REBOA组100%,两组间无显著差异。
- ALM-REBOA组在院前救治阶段心率和呼气末CO2显著低于单纯REBOA组,平均动脉压较基线显著下降但组间无显著差异。
- ALM在损伤后1分钟给药,7分钟后行Zone 1 REBOA充气,心脏停搏后可自行恢复或启动高级生命支持。
适用人群与场景
- 雄性约克夏猪,体重60-80 kg,通过右股动脉1.5 cm切开诱导非压迫性躯干出血模型。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 第一步:基线时通过右股动脉1.5 cm切开诱导非压迫性躯干出血并量化失血。
- 第二步:损伤后1分钟(S1)给予ALM(原文未提及具体剂量、途径和频次)。
- 第三步:给ALM后7分钟(T0)行Zone 1 REBOA充气。
- 第四步:若发生心脏停搏,心脏功能可自行恢复或启动高级生命支持。
- 第五步:T30时行外科止血并REBOA放气,复苏至T90安乐死。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:随机对照动物实验,样本量n=8/组,单中心。
- 人群:雄性约克夏猪60-80 kg,非压迫性躯干出血模型。
- 干预与对照:ALM-REBOA vs 单纯REBOA。
- 主要终点结果:总失血量ALM-REBOA组显著减少(17.75±2.04 vs 24.32±1.89 mL/kg,p=0.0499)。
- 关键次要终点:生存率ALM-REBOA 89% vs 单纯REBOA 100%,无显著差异;院前救治阶段ALM-REBOA组心率和呼气末CO2显著低于单纯REBOA组,平均动脉压较基线显著下降但组间无显著差异。
证据类型、等级与局限
- 证据类型:随机对照动物实验(猪模型)。
- 证据等级或推荐强度:原文未提及。
- 局限:动物模型、样本量小(n=8/组)、单中心、结论需进一步验证。
对床旁实践的改变
- 在猪模型中,ALM作为REBOA辅助可减少非压迫性躯干出血的失血量而不影响生存,支持其作为REBOA放置前的桥接治疗概念验证。
- 原文未提及适用与不适用人群、常见陷阱。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Uncontrolled hemorrhage is the leading cause of potentially survivable combat casualty mortality, with 86.5% of cases resulting from noncompressible torso hemorrhage. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally invasive technique used to stabilize patients with noncompressible torso hemorrhage; however, its application can take an average of 8 minutes to place. One therapeutic capable of bridging this gap is adenosine-lidocaine-magnesium (ALM), which at high doses induces a reversible cardioplegia. We hypothesize by using ALM as an adjunct to REBOA, the ALM-induced cardiac arrest will temporarily halt exsanguination and reduce blood loss, allowing for REBOA placement and control of bleeding.
METHODS: Male Yorkshire swine (60-80 kg) were randomly assigned to REBOA only or ALM-REBOA (n = 8/group). At baseline, uncontrolled hemorrhage was induced via a 1.5-cm right femoral arteriotomy, and hemorrhaged blood was quantified. One minute after injury (S1), ALM was administered, and 7 minutes later (T0), zone 1 REBOA inflation occurred. If cardiac arrest ensued, cardiac function either recovered spontaneously or advanced life support was initiated. At T30, surgical hemostasis was obtained, and REBOA was deflated. Animals were resuscitated until they were humanely euthanized at T90.
RESULTS: During field care phase, heart rate and end-tidal CO2 of the ALM-REBOA group were significantly lower than the REBOA only group. While mean arterial pressure significantly decreased from baseline, no significant differences between groups were observed throughout the field care phase. There was no significant difference in survival between the two groups (ALM-REBOA = 89% vs. REBOA only = 100%). Total blood loss was significantly decreased in the ALM-REBOA group (REBOA only = 24.32 ± 1.89 mL/kg vs. ALM-REBOA = 17.75 ± 2.04 mL/kg, p = 0.0499).
CONCLUSION: Adenosine-lidocaine-magnesium is a novel therapeutic, which, when used with REBOA, can significantly decrease the amount of blood loss at initial presentation, without compromising survival. This study provides proof of concept for ALM and its ability to bridge the gap between patient presentation and REBOA placement.
参考来源
- Stigall KS, Neidert LE, Morgan CG, et al. Therapeutic cardiac arrest as an adjunct to resuscitative endovascular balloon occlusion of the aorta: Bridging the gap from fatal hemorrhage to definitive surgical control in swine. J Trauma Acute Care Surg. 2021. PMID: 33502148. doi:10.1097/TA.0000000000003024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。